Multi-center, Randomized, Open-label, Parallel-group Study to Evaluate User Satisfaction With and Tolerability of the Low-dose Levonorgestrel (LNG) Intrauterine Delivery System (IUS) With 16 μg LNG/Day Initial in Vitro Release Rate (LCS16) in Comparison to a Combined Oral Contraceptive (COC) Containing 30 μg Ethinyl Estradiol and 3 mg Drospirenone (Yarina®) in Young Nulliparous and Parous Women (18 - 29 Years) Over 12 Months of Use (With an Option for Extended Use of LCS16 for up to 5 Years)
Latest Information Update: 22 Aug 2022
Price :
$35 *
At a glance
- Drugs Levonorgestrel (Primary) ; Drospirenone/ethinylestradiol
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Bayer
- 17 Aug 2022 Status changed from active, no longer recruiting to completed.
- 07 Dec 2021 Planned End Date changed from 1 Sep 2022 to 11 Aug 2022.
- 19 Jul 2017 Status changed from recruiting to active, no longer recruiting.